Enhanced downregulation of the p75 nerve growth factor receptor by cholesteryl and bis-cholesteryl antisense oligonucleotides

Antisense and Nucleic Acid Drug Development

Volumn 8, Issue 6, 1998, Pages 489-498

  Epa, W Ruwan ^a   Rong, Pei ^b   Bartlett, Perry F ^a   Coulson, Elizabeth J ^a   Barrett, Graham L ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHOLESTEROL; CYCLOHEXIMIDE; EXONUCLEASE; MESSENGER RNA; NERVE GROWTH FACTOR RECEPTOR; PROTEIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL STRAIN; CELL TRANSPORT; DOWN REGULATION; DRUG UPTAKE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0032424515     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1998.8.489     Document Type: Article

References (23)

1. ALAHARI, S.K., DEAN, N.M., FISHER, M.H., DELONG, R., MANOHARAN, M., TIVEL, K.L., and JULIANO, R.L. (1996). Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 50, 808-819.
2. ATKINSON, T., and SMITH, M. (1984). Solid phase synthesis of oligodeoxyribonucleotides by phosphite-triester method. In: Oligonucleotide Synthesis: A Practical Approach. M.J. Gait, ed. (IRL Press, Oxford), pp. 35-82.
3. BARRETT, G.L., and BARTLETT, P.F. (1994). The p75 nerve growth factor receptor mediates survival or death depending on the stage of sensory neuron development. Proc. Natl. Acad. Sci. USA 91, 6501-6505.
4. BARRETT, G.L., and GEORGIOU, A. (1996). The low-affinity nerve growth factor receptor p75 (NGFR) mediates death of PC12 cells after nerve growth factor withdrawal. J. Neurosci. Res. 45, 117-128.
5. BEAUCAGE, S.L. (1993). Oligonucleotide synthesis: Phosphoramidite approach. In: Protocols for Oligonucleotides and Analogs. S. Agrawal, ed. (Humana Press, Totowa, NJ), pp. 33-62.
6. BOUJRAD, N., HUDSON, J.R., JR., and PAPADOPOULOS, V. (1993). Inhibition of hormone-stimulated steroidogenesis in cultured Leydig tumor cells by a cholesterol-linked phosphorothioate oligodeoxynucleotide antisense to diazepam-binding inhibitor. Proc. Natl. Acad. Sci. USA 90, 5728-5731.
7. BOUTORINE, A.S., BOIZIAU. C., LE DOAN, T., TOULMÉ, J.-J., and HÉLÈNE C. (1992). Effect of the terminal phosphate derivatization of beta- and alpha-oligodeoxynucleotides on their antisense activity in protein biosynthesis, stability and uptake by eucaryotic cells. Biochimie 74, 485-489.
8. BOUTORINE, A.S., GUS'KOVA, L.V., IVANOVA, E.M., KOBETZ, N.D., ZARYTOVA, V.F., RYTE, A.S., YURCHENKO, L.V., and VLASSOV, V.V. (1989). Synthesis of alkylating Oligonucleotide derivatives containing cholesterol or phenazinium residues at their 3′-terminus and their interaction with DNA within mammalian cells. FEES Lett. 254, 129-132.
9. CHOW, T.Y., JUBY, C., and BROUSSEAU, R. (1994). Specific targeting of antisense oligonucleotides to neutrophils. Antisense Res. Dev.4,81-86.
10. CROOKE, S.T., GRAHAM, M.J., ZUCKERMAN, J.E., BROOKS, D., CONKLIN, B.S., CUMMINS, L.L., GREIG, M.J., GUINOSSO, C.J., KORNBRUST, D., MANOHARAN, M., SASMOR, H.M., SCHLEICH, T., TIVEL, K.L., and GRTFFEY, R.H. (1996). Pharmacokinetic properties of several novel Oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277, 923-937.
11. DE SMIDT, P.C., LE DOAN, T., DE FALCO, S., and VAN BERKEL, TJ. (1991). Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res. 19, 4695-4700.
12. EDER, P.S., DEVINE, R.J., DAGLE, J.M., and WALDER, J.A. (1991). Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res. Dev. 1, 141-151.
13. FRADE, J.M., RODRIGUEZ-TEBAR, A., and BARDE, Y.A. (1996). Induction of cell death by endogenous nerve growth factor through its p75 receptor. Nature 383, 166-168.
14. GRYAZNOV, S.M., and LLOYD, D.H. (1993). Modulation of Oligonucleotide duplex and triplex stability via hydrophobic interactions. Nucleic Acids Res. 21, 5909-5915.
15. KRIEG, A.M., TONKINSON, J., MATSON, S., ZHAO, Q., SAXON, M., ZHANG, L.M., BHANJA, U., YAKUBOV, L., and STEIN, C.A. (1993). Modification of antisense phosphodiester oligodeoxynucleotides by a 5′ cholesteryl moiety increases cellular association and improves efficacy. Proc. Natl. Acad. Sci. USA 90, 1048-1052.
16. LETSINGER, R.L., ZHANG, G.R., SUN, D.K., IKEUCHI, T., and SARIN, P.S. (1989). Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc. Natl. Acad. Sci. USA 86, 6553-6556.
17. LIMA, W.F., and CROOKE, S.T. (1997). Binding affinity and specificity of Escherichia coli RNase H1: Impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry 36, 390-398.
18. MACKELLAR, c., GRAHAM, D., WILL, D.W., BURGESS, S., and BROWN, T. (1992). Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups. Nucleic Acids Res. 20, 3411-3417.
19. MILLIGAN, J.F., MATTEUCCI, M.D., and MARTIN, J.C. (1993). Current concepts in antisense drug design. J. Med. Chem. 36, 1923-1937.
20. RABIZADEH, S., OH, J., ZHONG, L.T., YANG, J., BITLER, C.M., BUTCHER, L.L., and BREDESEN, D.E. (1993). Induction of apoptosis by the low-affinity NGF receptor. Science 261, 345-348.
21. 35S-labeled polyphosphorothioate oligodeoxyribonucleotides by use of hydrogen phosphonate chemistry. Anal. Biochem. 188, 11-16.
22. STEIN, C.A., PAL, R., DEVICO, A.L., HOKE, G., MUMBAUER, S., KINSTLER, O., SARNGADHARAN, M.G., and LETSINGER, R.L. (1991). Mode of action of 5′-linked cholesterol phosphorothioate oligodeoxynucleotides in inhibiting syncytia formation and infection by HIV-1 and HIV-2 in vitro. Biochemistry 30, 2439-2444.
23. TEMSAMANI, J., KUBERT, M., TANG, J., PADMAPRIYA, A., and AGRAWAL, S. (1994). Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res. Dev. 4, 35-42.